SCHEMBL25983451

SCHEMBL25983451

COC(=O)c1ccc2c(OC)cc(-c3cccc(F)c3)nc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.48
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 2/20 0.48
HPGD P15428 2/20 0.47
LMNA P02545 1/20 0.47
DHODH Q02127 2/20 0.45
PDGFRB P09619 1/20 0.44
PDGFRA P16234 1/20 0.44
PLA2G2A P14555 2/20 0.44
MAPT P10636 2/20 0.43
MAPK1 P28482 1/20 0.43
HSD17B10 Q99714 1/20 0.43
SDHB P21912 1/20 0.43
NAMPT P43490 1/20 0.42
CSNK2A1 P68400 2/20 0.42
CSNK2A2 P19784 1/20 0.42
CSNK2B P67870 1/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25983552 0.90 CSNK2A2 (0.53) SMN1; SMN2KDM4EALDH1A1HPGDLMNA
SCHEMBL25983554 0.89 KDM4E (0.48) SMN1; SMN2KDM4EALDH1A1HPGDLMNA
SCHEMBL25981004 0.87 ALDH1A1 (0.64) SMN1; SMN2KDM4EALDH1A1HPGDLMNA
SCHEMBL25983556 0.83 KDM4E (0.43) SMN1; SMN2KDM4EALDH1A1HPGDLMNA
SCHEMBL25982799 0.82 HPGDS (0.47) SMN1; SMN2KDM4EHPGDLMNAMAPT
SCHEMBL25983632 0.82 KDM4E (0.44) SMN1; SMN2KDM4EALDH1A1HPGDLMNA
SCHEMBL15579401 0.81 KDM4E (0.73) SMN1; SMN2KDM4EALDH1A1HPGDLMNA
SCHEMBL31212330 0.81 KDM4E (0.47) SMN1; SMN2KDM4EALDH1A1HPGDLMNA
SCHEMBL31212371 0.81 NPC1 (0.47) SMN1; SMN2KDM4EALDH1A1HPGDLMNA
SCHEMBL25983146 0.81 NPC1 (0.47) SMN1; SMN2KDM4EALDH1A1HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250145599-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS MRJA THERAPEUTICS, INC. 2025-05-08 US disclosed
CN-118974019-A Certain chemical entities, compositions and methods 瑞图恩制药公司 2024-11-15 CN disclosed
WO-2023150663-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS RETUNE PHARMA INC. (US) 2023-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145599-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS IGF1R, IGFBP1, IGFBP2 SMN1; SMN2 1317/4885KDM4E 3842/4885ALDH1A1 826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.